Eagerly awaited trial data from Amgen’s latest KRAS-targeting cancer drug AMG 510 emerged over the weekend – and the results have received broadly positive reviews.
An investigational lung cancer drug from Novartis and Incyte could be on the market midway through next year after the FDA agreed to expedite development and review in a tough to treat form
NICE has recommended the NHS should fund Novartis’ Luxturna for a rare eye disorder, after the company agreed a discount from the list price of more than £613,000 per patient.
Novartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar of Biogen’s multiple sclerosis drug Tysabri (natalizumab).<
